spinal muscular atrophy

Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Novartis mulling $1.5 mln-$5 mln price range for SMA gene therapy
Yahoo/Reuters
Novartis
Zolgensma
gene therapy
drug pricing
spinal muscular atrophy
Flag link:
Ionis slides after AveXis reports SMA data for Zolgensma
Ionis slides after AveXis reports SMA data for Zolgensma
BioCentury
Ionis Pharmaceuticals
AveXis
Zolgensma
lcinical trials
spinal muscular atrophy
Flag link:
With FDA decision near, Novartis bolsters SMA gene therapy case
With FDA decision near, Novartis bolsters SMA gene therapy case
Biopharma Dive
Novartis
FDA
Zolgensma
spinal muscular atrophy
Flag link:
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Novartis' SMA gene therapy would not be cost-effective if priced over $1.5M: ICER
Fierce Pharma
Novartis
ICER
drug pricing
Zolgensma
gene therapy
spinal muscular atrophy
Flag link:
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
ICER's life year calculation gives Novartis wider pricing ballpark for SMA therapy
BioCentury
Novartis
Zolgensma
AVXS-101
spinal muscular atrophy
ICER
Flag link:
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Novartis: Alternative payments will ‘reset the paradigm’ for covering gene, cell therapies
Fierce Pharma
Novartis
ICER
spinal muscular atrophy
alternative payments
drug pricing
gene therapy
Zolgensma
Flag link:
ICER says gene therapy may be more cost effective for spinal muscular atrophy
ICER says gene therapy may be more cost effective for spinal muscular atrophy
Yahoo/Reuters
Biogen
Spinraza
Novartis
spinal muscular atrophy
ICER
Flag link:
US benefits manager baulks after Novartis values gene therapy at $4-5 mln
US benefits manager baulks after Novartis values gene therapy at $4-5 mln
Yahoo/Reuters
Novartis
Express Scripts
SMA
spinal muscular atrophy
drug pricing
AVXS-101
Flag link:
Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
Sticker shock: Novartis says its top drug prospect is worth $4M-$5M for a once-and-done use
Endpoints
Novartis
drug pricing
AVXS-101
spinal muscular atrophy
Flag link:
Biogen's new Spinraza data for earlier use 'pretty amazing,' analyst says
Biogen's new Spinraza data for earlier use 'pretty amazing,' analyst says
Fierce Pharma
Biogen
Spinraza
spinal muscular atrophy
SMA
Flag link:
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
CP Wire
Genentech/Roche
risdiplam
spinal muscular atrophy
Flag link:
Genentech Announces New Data for Risdiplam in Spinal Muscular Atrophy in Infants
Genentech/Roche
risdiplam
spinal muscular atrophy
Flag link:
[video+transcript]Gene Therapy Could Be a Boon for This Biotech
[video+transcript]Gene Therapy Could Be a Boon for This Biotech
Motley Fool
gene therapy
Rengexbio
spinal muscular atrophy
wet age-related macular degeneration
Flag link:
Biogen's Spinraza gets an early no-go from NICE
Biogen's Spinraza gets an early no-go from NICE
Biopharma Dive
Biogen
UK
NICE
Spinraza
SMA
spinal muscular atrophy
Flag link:
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Why PTC Therapeutics Dropped 30.6% Today After Jumping 27.5% Yesterday
Motley Fool
PTC Therapeutics
risdiplam
Biogen
Ionis Pharmaceuticals
spinal muscular atrophy
Sarepta Therapeutics
Translarna
Emflaza
Flag link:
After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom
After a crushing PhIII failure, Cytokinetics says its next-gen muscle drug is lining up well in PhII — but big challenges loom
Endpoints
Cytokinetics
clinical trials
reldesemtiv
Tirasemtiv
spinal muscular atrophy
Astellas
Flag link:
Roche scraps €120M SMA drug after hitting ‘many difficulties’
Roche scraps €120M SMA drug after hitting ‘many difficulties’
Fierce Biotech
Roche
SMA
spinal muscular atrophy
Olesoxime
Flag link:
Biogen’s Spinraza Sales Slow as AveXis and Novartis Pursue SMA Gene Therapy
Biogen’s Spinraza Sales Slow as AveXis and Novartis Pursue SMA Gene Therapy
Xtalks
Biogen
earnings
Spinraza
spinal muscular atrophy
Flag link:
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
First Patient Dosed in Avexis' Phase 3 Trial of AVXS-101 in Pre-Symptomatic Spinal Muscular Atrophy
CP Wire
AveXis
Novartis
M&A
clinical trials
AVXS-101
gene therapy
spinal muscular atrophy
Flag link:
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Novartis buying AveXis for $8.7 billion to strengthen gene therapy capabilities
Stat
Novartis
M&A
AveXis
gene therapy
AVXS-101
SMA
spinal muscular atrophy
Flag link:

Pages